期刊文献+

替吉奥结合规范化辅助治疗在Ⅲ期结直肠癌患者临床治疗中的应用

下载PDF
导出
摘要 目的:探究替吉奥结合规范化辅助治疗在Ⅲ期结直肠癌患者临床治疗中的应用效果。方法:选取2016年1月到2018年1月我院收治的Ⅲ期结直肠癌晚期患者72例作为研究对象,根据患者的化疗方法不同将患者均分为实验组与对照组,各36例,对照组患者仅采用规范化辅助治疗,实验组患者采用替吉奥结合规范化辅助治疗,对比两组患者的3年内存活率和总生存率。结果:两组患者的3年存活率相比,实验组患者3年存活率显著高于对照组,统计学意义存在(P<0.05);实验组患者的总生存率与对照组患者相比,有统计学意义(P<0.05)。结论:替吉奥结合规范化辅助治疗在Ⅲ期结直肠癌患者中应用效果良好,可有效提高患者的3年生存率、总生存率,该种治疗方法值得在临床中推广。
作者 王春英
出处 《现代消化及介入诊疗》 2018年第A02期134-134,共1页 Modern Interventional Diagnosis and Treatment in Gastroenterology
  • 相关文献

参考文献6

二级参考文献62

  • 1CHEN Wei-chang,LIN Mao-song,BAI Xia.Induction of apoptosis in colorectal cancer cells by peroxisome proliferators-activated receptor γ activation up-regulating PTEN and inhibiting PI3K activity[J].Chinese Medical Journal,2005(17):1477-1481. 被引量:14
  • 2Jemal A, Murray T, Ward E, et al. Cancer statistics 2007 [ J ]. CA Cancer J Clin, 2007, 57:43 - 66.
  • 3Giantonio B J, Catalano PJ, Meropol N J, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group(ECOG) study E3200 (abstract2) [ J ]. J Clin Oncol, 2005, 23(supple16S) : 1s.
  • 4Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer( mCRC ) : Final analysis of the TREE-Study ( abstract3510 ) [J]. J Clin Oncol, 2006, 24( suppl 18S) : 148s.
  • 5Kabbinavar FF, Schulz J, McCieod M,et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase Ⅱ trial [ J ]. J Clin Oncol,2005, 23(16) : 3697 -3705.
  • 6Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage Ⅲ colon cancer [ J ]. N Engl J Med, 2005,352 ( 26 ) : 2696 - 2704.
  • 7Diaz RE, Tabemero J, van CE, et al . Cetuximab in combination with oxaliplatin/5 -fluorouracil ( 5 -FU )/folinic acid (FA) ( FOLFOX- 4 ) in the first-line treatment of patients with Epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase Ⅱ study ( abstract 3555 ) [J]. J Clin Oncol,2005, 23 ( suppl 16s) : 254s.
  • 8Van Cutsem E, Nowacki E, Lang I, et al. Randomized phase Ⅲ study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC) : The CRYSTAL trial ( abstract4000 ) [ J ]. J Clin Oncol, 2007, 25( suppl 18s) : 164s.
  • 9Venok A, Niedzwiecki D, Hollis D, et al. Phase Ⅲ study of irinotecan/SFU/LV(FOLFIRI) or oxaliplatin/5FU/LV(FO;FOX) ± cetuximab for patients (pts) with untreated metastatic adenocareinoma of the colon or rectum (MCRC) :CALGB 80203 preliminary results (abstract 3509) [ J]. J Clin Oncol,2006, 24( suppl 18s) : 148s.
  • 10Quirke P. Training and quality assurance for rectal cancer: 20years of data is enough. Lancet Oncol, 2003,4( 11) :695-702.

共引文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部